261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2. (12th April 2019) - Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan; Blanco, Richardo; Cohen, Martin; Delicha, Eumorphia-Maria; Rohrer, Susanne; Richards, Hanno